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INTRODUCTION
Patients with type 2 diabetes are at high risk of
developing cardiovascular diseases (CVDs) and,
consequently of reduced life expectancy. Type 2
diabetes may remain undiagnosed for many years, and
at diagnosis complications are frequently present.1,2
There is increasing evidence that early detection and
treatment of type 2 diabetes is beneficial, although
definitive studies are lacking.3,4
To improve the prognosis of people with type 2
diabetes, prevention of CVD is needed. Intensive
treatment of hyperglycaemia, hypertension, and
dyslipidaemia can reduce the CVD risk.5–7 It has been
demonstrated that multifactorial intervention in
patients with diabetes with microalbuminuria slows
cardiovascular and microvascular complications.8,9
However, it has not been investigated whether
intensified, multifactorial treatment of patients with
screen-detected diabetes can reduce CVD mortality
and the incidence of macro- and microvascular
complications. To this purpose, the ADDITION study
(Anglo-Danish-Dutch Study of Intensive Treatment in
People with Screen-Detected Diabetes in Primary
Care) has been initiated.10 Patients with diabetes
ABSTRACT
Background
A growing body of evidence suggests that earlier
diagnosis and treatment of diabetes may be beneficial;
however, definitive evidence is lacking.
Aim
To evaluate the effectiveness of an intensified
multifactorial treatment on cardiovascular risk factors in




Seventy-nine general practices in the southwestern
region of the Netherlands.
Method
In this randomised trial, patients diagnosed with
diabetes by screen-detection were assigned to
intensified (n = 255) or routine treatment (n = 243), and
followed over 1 year. Intensified treatment consisted of
pharmacological treatment combined with lifestyle
education to achieve haemoglobin A1c (HbA1c)
<7.0%, blood pressure <135/85 mmHg, and
cholesterol <5.0 mmol/l (4.5 mmol/l if cardiovascular
disease was present). Health-related quality of life
(HRQoL) was assessed using the Short Form (SF)-36.
Analyses were performed using generalised estimating
equations models.
Results
Changes in body mass index were 0.2 (routine care)
versus –1.4 kg/m2 (intensified treatment), P<0.001;
systolic blood pressure –19 versus –33 mmHg,
P<0.001; diastolic blood pressure –7 versus –12 mmHg,
P<0.001; HbA1c –0.9% versus –1.1%, P = 0.03;
cholesterol –0.5 versus –1.2 mmol/l, P<0.001; high-
density lipoprotein cholesterol 0.1 versus 0.1 mmol/l, P
= 0.26; low-density lipoprotein cholesterol –0.5 versus
–1.0 mmol/l, P<0.001; triglycerides –0.3 versus
–0.4 mmol/l, P = 0.71. No difference in HRQoL between
the two groups was reported.
Conclusion
Intensified multifactorial treatment of patients with
screen-detected diabetes in general practice reduces
cardiovascular risk factor levels significantly without
worsening HRQoL.
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identified by screening tend to trivialise the seriousness
of their condition.11 Consequently, an intensified
intervention might be experienced as too burdensome
which could limit the feasibility of such an approach.
This paper reports the 1-year results of the
ADDITION Netherlands study. The aim of this study
was to investigate whether an intensified, multifactorial
treatment resulted in more favourable cardiovascular
risk profiles in patients with screen-detected type 2
diabetes compared with those who received routine




This study is part of the international ADDITION study
which is a randomised controlled intervention trial of
3057 patients with screen-detected diabetes.10,13
ADDITION consists of a screening study and a
subsequent intervention trial with a follow-up of
5 years. In the intervention trial the effects of routine
care in general practice according to national
guidelines are compared with those of an intensified,
multifactorial treatment on mortality and cardiovascular
morbidity.
In the ADDITION Netherlands study, from 2002 to
2004, a total of 56 978 non-diabetic registered patients
aged 50–70 years from 79 general practices in the
southwestern region of the Netherlands were invited to
participate in a stepwise population-based screening
programme. The screening algorithm has been
described in detail elsewhere.14 The screening started
with a self-completed questionnaire based on a
validated risk score.15 Participants with a risk score
above threshold were invited for further diagnostic
testing. Diagnosis of diabetes was based on the 1999
World Health Organization definition.16 In total, 586 new
patients with diabetes were detected.14
Study design
ADDITION Netherlands is a multipractice trial with
practice-level randomisation to intensified treatment or
routine care. Patients were blinded to which treatment
arm their GP had been randomised to. The intensive
treatment protocol was carried out by a diabetes nurse
together with a GP.
GPs and practices
Approximately 500 GPs in the region, all cooperating
with one regional laboratory (SHL Centre for Diagnostic
Support in Primary Care, Etten-Leur, the Netherlands),
were invited to participate with an informative letter
about the study. Subsequently, all GPs were contacted
by telephone. Inclusion criteria for the participating
GPs were attendance at an instruction meeting,
agreement that all GPs in the practice or partnership
would participate in the ADDITION study, and
agreement to treat all patients with screen-detected
diabetes according to the randomly allocated
treatment protocol. A total of 79 practices were
randomly selected from those willing to participate.
Randomisation was performed according to
stratification of practice organisation (single-handed,
group practices).
In 41% of the practices in the intensified treatment
group, and in 52% of the practices in the routine care
group, practice nurses were involved in daily
diabetes care.
Patients
In the Netherlands, the entire population is registered
with a GP. Therefore, the screened population may be
considered to be a representative sample of the full
population. The invitation letter was sent to the
patients’ home addresses and signed by their own GP.
The letter explained the aim of the study; also enclosed
with the letter were an informed consent form and a
questionnaire for self-completion which contained
questions about age, sex, body mass index, family
history of diabetes, frequent thirst, use of
antihypertensive medication, shortness of breath,
claudication, and exercise such as cycling.
Exclusion criteria were any contraindications to or
history of major intolerance to any of the drugs used in
the study; a history of alcoholism, drug abuse,
psychosis, personality disorder, or another emotional,
psychological, or intellectual problem that is likely to
invalidate informed consent or limit the ability to
comply with the protocol requirements; and/or being
treated for a malignant disease or otherwise having a
poor prognosis.
Details of the intervention
Intensively treated group.During a 3-hour session, GPs
were trained in the treatment protocol. This protocol is
characterised by intensive treatment of glucose, blood
pressure, and lipids, and structured lifestyle education
(dietary modification, weight loss, increased physical
activity, smoking cessation and improving adherence
to medication).
Haemoglobin A1c (HbA1c) level should be kept
under 7.0%. Alternations or additions to glucose-
lowering therapy should already be initiated when
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How this fits in
Early detection and treatment of type 2 diabetes might be beneficial, although
conclusive evidence is not available. Intensified multifactorial treatment of
patients with screen-detected type 2 diabetes in general practice is feasible and
reduces the levels of cardiovascular risk factors significantly. At end of this
study no differences in health-related quality of life between the intensively
treated group and the routine care group were found.
HbA1c >6.5%. If HbA1c remains above 7.0% with oral
agents, insulin therapy should be initiated.
Antihypertensive agents were prescribed if blood
pressure was >120/80 mmHg (systolic or diastolic).
Angiotensin-converting enzyme (ACE) inhibitors were
the initial treatment unless there were side-effects. In
that case an angiotensin-II receptor antagonist was
prescribed. If blood pressure was >135/85 mmHg, the
dose had to be increased, and calcium channel
blockers, thiazides, or beta-blockers were added with
a stepwise approach. Treatment with a statin was
indicated if cholesterol was >5.0 mmol/l or >4.5 mmol/l
in patients without or with a known history of CVD
respectively. The dose of statin was increased up to
maximum if cholesterol remained above threshold. In
2003 the protocol changed: all participants with
cholesterol >3.5 mmol/l were treated with lipid-
lowering drugs. Acetylsalicylic acid 80 mg per day was
given to patients treated with antihypertensive agents.
Diabetes nurses were trained in the management of
the treatment algorithms and in providing lifestyle
education. They were authorised to prescribe
medication, supervised by the GPs. During the first year
of the intervention, every 3 months a 2-hour training
session was arranged. Objectives of these sessions
included discussing obstacles in reaching the target
values, exchanging experiences, and evaluating
cooperation with GPs. At least once per year, GPs from
the intervention group were reminded about treating
their ADDITION patients according to the protocol.
Patients diagnosed with type 2 diabetes were first
seen by their GP. Subsequently, visits were paid to the
diabetes nurse at least 2, 4, 6, 8, and 12 weeks after
diagnosis until target levels were reached. Thereafter,
patients were requested to visit the GP or nurse every
3 months. One year after screening, an extensive visit
to the GP took place. Patients were referred to an
internist if the diabetes nurse and GP did not succeed
in reaching the targets.
Routine care group. According to the 1999 guidelines
from the Dutch College of General Practitioners,12 the
target value for HbA1c was <7.0%. However, in the
guidelines HbA1c levels between 7.0% and 8.5%were
described as acceptable. Lipid-lowering drugs should
be initiated if participants without a known history of
CVD had a risk above 25% of developing a coronary
disease within 10 years. Participants with previous
CVD should be treated with lipid-lowering medication if
cholesterol >5.0 mmol/l. If blood pressure was
>150/85 mmHg, treatment was recommended starting
with a thiazide diuretic. Subsequently, an ACE inhibitor
or a beta-blocker could be added, or the combination
of thiazide, ACE inhibitors, and beta-blockers was
given. Detailed instructions about providing lifestyle
education were not given.12 After the initiation
symposium, no further training of GPs was provided.
Measurements
Blood pressure was measured using an Omron M4
blood pressure recorder (Omron Healthcare, Milton
Keynes, UK). Fasting blood glucose was determined
with a HemoCue B-Glucose Analyser based on the
glucose-dehydrogenase method (HemoCue,





















88 patients excluded (34 routine, 54 from 
intervention practices): 12 psychological or 
intellectual problems; 5 with a malignancy or 
poor prognosis; 1 already had diabetes;
1 had a contraindication; 69 declined participation
Figure 1. Trial profile.
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Angelholm, Sweden). HbA1c was measured with high-
performance liquid chromatography (160 A. Menarini
Diagnostics, Firenze, Italy). Lipids were determined
with enzymatic techniques (LX20 Beckman, Fullerton,
CA, US). All biochemical tests were performed in the
regional laboratory.
Laboratory results were extracted from the regional
laboratory where all patients were examined regularly,
independent of intervention arm. Blinded data
collection was done by research assistants. In the
routine care group, data were derived from patients’
files at the practices, and in the intervention group data
were derived from case record forms.
Prior to entry into the study, participants completed
the Short Form (SF)-36, a validated instrument
designed for the self-evaluation of health-related
quality of life (HRQoL).17,18 The SF-36 measures general
health, vitality, mental health, physical functioning,
limitations due to physical difficulties (role physical),
bodily pain, social functioning, and limitations due to
emotional difficulties (role emotional). For each
dimension, scores range from 0 (worst health) to 100
(best health).
Statistical analyses
Analyses were performed using generalised estimating
equations models, adjusting for age, sex, baseline
values, and clustering at practice level.
SF-36 scores at the end of the study were analysed
using analysis of covariance with age, sex, and
baseline values as covariates to adjust for differences
between treatment groups at randomisation. Paired-
samples t-tests were used to compare baseline with
follow-up within each treatment group.
Analyses were based on intention-to-treat. Last
available measurements were used for participants
who were lost to follow-up, and for missing data. P-
value <0.05 was considered statistically significant.
Data were analysed using the SPSS statistical package
(version 15.0). The CONSORT checklist for cluster
randomised controlled trials was adhered to.
RESULTS
Of the 586 patients with screen-detected diabetes, 498
were included. A total of 255 participants were
assigned to intensified treatment and 243 to routine
care. Excluded from the study were 88 people: 69
declined participation, 12 had psychological or
intellectual problems, five had a poor prognosis, one
person already had diabetes, and one had a
contraindication.
The trial profile is shown in Figure 1. Of all 498
included patients, seven (two in the routine care group,
five in the intensively treated group) were lost to follow-
up for various reasons (relocation, withdrawal of
consent, treatment too burdensome). Reasons for
study discontinuation were similar between both
treatment groups.
The two groups were well matched with respect to
clinical, biochemical, and behavioural characteristics
(Table 1), as well as use of cardiovascular medications
and history of cardiovascular events (data not shown).
With the exception of high-density lipoprotein (HDL)-
cholesterol and triglycerides, variables improved
significantly better after 1 year in the intensively treated
group compared with the routine care group. One
hypoglycaemic event (requiring assistance) occurred in
the intervention group.
SF-36 scores between both treatment groups at the
end of the study were not significantly different (Table
2). Within both treatment groups, general health, vitality
and mental health, and in the intensively treated group
also physical functioning, improved significantly during
follow-up. Scores on social functioning decreased
equally in both groups.
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Routine care Intensive treatment
(n = 243) (n = 255) P-valuea
Baseline 1 year Baseline 1 year
Demographic variables
Sex, % male 56.0 51.8
Age in years, mean (SD) 59.9 (5.1) 60.1 (5.4)
Ethnicity, % white 98.7 98.0
Behavioural variables
Current smoking, % 21.4 26.3
Ever smoked, % 68.0 66.1
Drinking alcohol, % 78.1 78.4
Weekly >5 pieces of fruit, % 61.7 57.6
Exercise (days per week 3.8 (2.5) 4.0 (2.3)
>30 min), mean (SD)
Clinical variables, mean (SD)
Body mass index, kg/m2 30.4 (4.6) 30.6 (4.8) 31.2 (5.1) 29.8 (4.8) <0.001
Systolic blood pressure, 163 (23) 144 (17) 166 (23) 133 (17) <0.001
mmHg
Diastolic blood pressure, 89 (10) 82 (8) 90 (11) 78 (9) <0.001
mmHg
Biochemical variables, mean (SD)
Fasting blood glucose, 8.1 (2.8) 7.2 (1.7) 7.8 (2.3) 6.5 (1.1) 0.02
mmol/l
HbA1c, % 7.4 (1.7) 6.5 (0.9) 7.3 (1.6) 6.2 (0.6) 0.03
Cholesterol, mmol/l 5.6 (1.1) 5.1 (1.0) 5.6 (1.1) 4.4 (0.9) <0.001
HDL-cholesterol, mmol/l 1.1 (0.3) 1.2 (0.9) 1.1 (0.4) 1.1 (0.3) 0.26
LDL-cholesterol, mmol/l 3.7 (1.0) 3.2 (1.0) 3.7 (1.0) 2.7 (0.8) <0.001
Triglycerides, mmol/l 2.0 (1.6) 1.7 (1.7) 1.9 (1.0) 1.5 (0.8) 0.71
Practices, %
Single-handed 50.0 43.2
Urban location 52.4 29.7
Specific diabetes clinic 63.4 62.2
>10% patients from ethnic 7.1 8.1
minority groups
aComparison of changes in variables between treatment groups adjusted for age, sex, baseline
value, and clustering at practice level. HbA1c = Haemoglobin A1c. HDL = high-density
lipoprotein. LDL = low-density lipoprotein.
Table 1. Baseline characteristics and changes in biomedical
variables after 1 year in both treatment groups.
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DISCUSSION
Summary of main findings
In this randomised controlled trial, patients with
screen-detected type 2 diabetes in general practice
were followed for 1 year. In patients assigned to
intensified multifactorial treatment, clinical and
biochemical variables improved significantly more than
in those who received routine care. The study findings
showed cardiovascular risk factors to be considerably
modifiable by an intensified, multifactorial treatment in
a population at high risk for developing cardiovascular
complications. At the end of follow-up, SF-36 scores
were similar for the two arms, suggesting no major
detrimental impact on quality of life from the intensive
intervention.
Strengths and limitations of the study
Some limitations should be taken into account in
interpreting the results of this study. Patients in the
intensive armwere treated by diabetes nurses who had
enough time to motivate patients. Therefore, it might
be disputed whether the treatment targets achieved in
this trial are also achievable in daily practice. However,
in many general practices, specialised nurses are
already involved in daily diabetes care, making the
implementation of an intensified treatment feasible.
GPs in the routine care practices followed the 1999
Dutch guidelines on type 2 diabetes.12 These guidelines
were updated in 2006. It should be emphasised that it
is not possible to rule out that in advance of the 2006
guidelines these GPs might already have tended
towards tighter control for cardiovascular risk factors.
As a result, the impressive differences in biomedical
variables between both treatment groups after 1 year
of treatment might become less so later on. Numbers
of missing 1-year data were comparable between both
groups. Analyses were based on intention-to-treat,
with the last value carried forward for missing data.
Given the strong decrease in cardiovascular risk factor
levels in the intervention arm, the decrease might be
even greater when no data would have been missing.
In the routine care group, considerably more urban
practices were included. However, great similarities
were found between baseline cardiovascular risk factor
levels in urban and rural practices (data not shown).
A strength of this trial is that the study population
was unselected. To the authors’ knowledge, this is the
first randomised trial on the effects of an intensive,
multifactorial intervention in patients with type 2
diabetes identified by screening. Participants in
landmark trials on cardiovascular risk, such as the
Heart Protection Study, the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial, the
UK Prospective Diabetes Study, the ADVANCE study,
or the ACCORD trial, were not intensively treated for all
known cardiovascular risk factors together.19–23
Comparison with existing literature
Another randomised trial in general practice to assess
the effect of a multifaceted intervention was carried out
in Denmark.24 This study included clinically diagnosed
patients with type 2 diabetes. GPs were assigned to
routine care or structured care. In the intervention
group, GPs were supported by prompting, feedback,
and clinical guidelines to reach individualised targets.
After 6 years of follow-up, differences between both
groups were seen for fasting plasma glucose, HbA1c,
and systolic blood pressure, but not for smoking
habits, exercise, diastolic blood pressure, cholesterol,
and triglycerides. At the end of the study, no
differences were found in occurrence of myocardial
infarction, stroke, or diabetic retinopathy. The
treatment goals in this trial were less ambitious than
those in the ADDITION study. In the Steno type 2 study,
in which diabetic patients with microalbuminuria were
included, cardiovascular event rate was cut by half in
the intensively treated group (mean follow-up
7.8 years).8,9 Nevertheless, the event rate was
47
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Routine care Intensive treatment Difference between groupsc
(n = 243) (n = 255) P-value
Baseline 1 year Baseline 1 year
General health 59.7 (12.0) 64.4 (18.1)b 59.1 (11.5) 63.3 (18.4)b 0.632
Vitality 52.2 (13.2) 67.1 (18.4)b 49.3 (14.4) 64.8 (20.4)b 0.814
Mental health 69.9 (12.6) 79.0 (15.6)b 68.4 (13.3) 75.9 (17.9)b 0.559
Physical functioning 78.3 (22.0) 78.1 (23.2) 77.4 (21.9) 80.1 (21.2)b 0.218
Role physical 84.9 (30.0) 81.1 (33.5) 82.8 (31.4) 80.3 (35.0) 0.930
Bodily pain 84.7 (20.7) 82.2 (22.4) 80.8 (22.1) 79.2 (22.7) 0.970
Social functioning 89.0 (17.2) 85.7 (19.2)b 87.9 (20.0) 83.0 (22.0)b 0.368
Role emotional 85.4 (32.4) 89.9 (26.0) 88.2 (28.6) 86.2 (30.9) 0.254
aData are mean (SD). bDifference between baseline and at end of study within group is significant. cDifferences between
treatment groups at end of study, adjusted for age, sex, and baseline value.
Table 2. Short Form-36 scores at baseline and after 1-year follow-up in both
treatment groups.a
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considerable (3.5%) in this high-risk population.
Improvements in SF-scores found in the present
study were not seen in the Dutch Hoorn study which
included patients with screen-detected diabetes, aged
50–75 years, who received routine care after screening.
Baseline and 1-year SF-36 scores in the Hoorn study
did not differ substantially, except for the dimension
‘role emotional’.25 In the US, HRQoL scores at baseline
and after 1 year were similar for persons with and
without diabetes found at screening, and remained
practically unaltered over the year after screening.26
SF-36 scores between both treatment groups at the
end of the study were not different. With two groups of
250 patients, it is possible to detect a difference of 5.0
between the SF-36 scores (standard deviation 20,
power 80%, two-sided alpha 0.05). This means that
subtle differences in SF-36 scores cannot be detected
with the present study population.
Implications for future research and clinical
practice
The results of this study indicate that an intensified,
multifactorial treatment for patients with screen-
detected type 2 diabetes in general practice is feasible,
at least in the short term, and reduces the levels of
cardiovascular risk factors significantly without
worsening HRQoL. Final results of the ADDITION study
in 2010 must be awaited to evaluate the beneficial
effect of this intensified intervention on the
development of cardiovascular events in patients with
screen-detected diabetes. The primary endpoint for
the 5-year follow-up will be a composite cardiovascular
outcome comprising cardiovascular mortality and
morbidity (myocardial infarction, non-fatal stroke),
revascularisations, and amputations.13
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